Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Infosys - A Case Of Great Expectations - Nirmal Bang

Posted On: 2013-03-31 20:33:20

Infosys' stock has rallied nearly 25% over the past two-odd months following betterthan-expected 3QFY13 results. In our view, such a steep upward move implies great expectations of the street regarding an improved performance in FY14. While we expect Infosys to increase its revenue at a faster rate in FY14, we believe it will come at the cost of margins, given the need to show flexibility in pricing and deal structuring; 3QFY13 EBIT margin was at a 22-quarter low and we have factored in 113bps YoY EBIT margin decline in FY14E. We expect this to impede earnings growth and have factored in 7.6% EPS CAGR over FY13E-FY15E; the current valuation of 14.9x FY15E EPS is not cheap and under-performance against high expectations could trigger a correction. We have retained Sell rating on Infosys with a revised TP of Rs2,685 (Rs2,310 earlier), rolling over our valuation multiple to FY15.

Stock surge implies great expectations, revenue growth seen at the cost of margins: Infosys' stock has surged nearly 25% over the past two-odd months following better-thanexpected 3QFY13 results. In our view, such a steep move implies great expectations of an improved performance in FY14. While we expect Infosys to grow its revenue faster in FY14, it will be at the cost of margins because of a highly competitive market and the need to show flexibility in pricing and deal structuring (read make upfront investments).

Margins to remain under pressure; 3Q EBIT margin at a 22-quarter low: As we have stated above, while we expect FY14E revenue growth to be better than FY13E (13.6% versus 6.5%), we believe it will come at the cost of margins, given the need to be more flexible on pricing and deal structuring. We believe it is a trade-off, an 'either-or' situation as regards revenue growth and margins, and in the wake of revenue market share loss over the past many quarters (refer Exhibits 1 and 2), we expect Infosys to opt for the former. It should be noted that while 3QFY13 revenue growth was impressive, EBIT margin was at its lowest level since 1QFY08 (22 quarters). We expect 113bps fall in FY14E EBIT margin (25.1% versus 26.3% in FY13E), led mainly by higher employee costs.

Financial services budgets likely to shrink in CY13/FY14: Infosys sees IT budgets in the key financial services vertical shrinking in CY13/FY14 owing to muted growth prospects of its clients across all major segments - banking, capital markets and insurance. Greater focus is likely on run-the-business initiatives for cost savings. In our view, this could lead to some pricing pressure in this vertical. Given that financial services contributed 33.7% to 3QFY13 revenue, by far Infosys' largest vertical, this could prove to be a headwind for FY14 revenue growth.

Margin pressure to lead to tepid EPS CAGR of 7.6% over FY13E-FY15E, retain Sell: While we expect higher revenue growth in FY14 for Infosys compared with FY13, we expect the pressure on margins to lead to a tepid EPS CAGR of just 7.6% over FY13EFY15E. The stock currently trades at 14.9x FY15E EPS, which in our view is not cheap in the light of slow EPS growth expected by us. We believe the possibility of disappointment on high expectations could trigger a stock price correction. We have retained our Sell rating on the stock with a revised target price of Rs2,685 (Rs2,310 earlier), rolling over our valuation multiple to FY15.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views on Dishman Pharmaceuticals 1QFY2016 Result - Angel Broking
Views on Aurobindo Pharma receives USFDA Approval for Raloxifene Hydrochloride Tablet: Angel Broking
Buy SKS Microfinance - Anand Rathi Research
Linc Pen & Plastics - Soft crude prices to boost profitability - Angel Broking
Views on Aurobindo Pharma receives USFDA Approval for Entecavir Tablets
Bandhan: How difficult it is to operate as a bank? - Religare Capital Market
Views on Impact of Rupee Depreciation on IT & Pharmaceuticals - Angel Broking
Views on Aurobindo Pharma receive USFDA Approval for Omeprazole & Ibandraonate Sodium - Angel Broking
Views on Lupin gets USFDA nod for Fenofibrate Tablets - Angel Broking
Views on Sun Pharma announce US FDA approval for Ximino™ - Angel Broking
Oil India - Q1: Subsidy burden impacts PAT - AXIS Capital
Tube Investments: Muted Q1; gradual recovery ahead - AXIS Capital
Astral Polytechnik: Q1 muted; gradual recovery ahead - AXIS Capital
Views on BEML Limited 1QFY2016 Results - Angel Broking
Views on Indag Rubber 1QFY2016 Results - Angel Broking
Views on KNR Constructions Limited 1QFY2016 Results - Angel Broking
Views on Amara Raja Batteries Ltd (ARBL) 1QFY2016 Results - Angel Broking
Views on MBL Infrastructure Ltd 1QFY2016 Results - Angel Broking
Views on on Coal India 1QFY2016 Results: Angel Broking
July CPI inflation eases, production up: DBS Group Research
Views on Cadila Healthcare 1QFY2016 Results - Angel Broking
Views on India Cement 1QFY2016 Results - Angel Broking
Views on IDBI Bank 1QFY2016 Results - Angel Broking
Views on Ashok Leyland Ltd 1QFY2016 Results - Angel Broking
Views on JK Lakshmi Cements 1QFY16 Results - Angel Broking
Views on Sun Pharmaceuticals 1QFY2016 Results - Angel Broking
Views on Tata steel 1QFY2016 Results - Angel Broking
Views on Apollo Tyres Ltd 1QFY2016 Results - Angel Broking
Views on State Bank of India 1QFY2016 Results - Angel Broking
Views on Minda Industries Ltd 1QFY2016 Results - Angel Broking
Views on Power Grid Corp 1QFY2016 Results - Angel Broking
Views on Garware Wall Ropes 1QFY2016 Results - Angel Broking
Views on Radico Khaitan 1QFY2016 Results - Angel Broking
Views on IL&FS Transportation Network 1QFY2016 Results - Angel Broking
Views on Mangalam Cement 1QFY2016 Results: Angel Broking
Views on PNC Infratech 1QFY2016 Results: Angel Broking
Views on Tata Motors 1QFY2016 Results: Angel Broking
Views on Mahindra & Mahindra 1QFY2016 Results: Angel Broking
MT Educare 1QFY2016 Results: Angel Broking
Views on Canara Bank 1QFY2016 Results: Angel Broking
Views on Shree Cement 4QFY2015 Results: Angel Broking
Views on Orient Cement 1QFY2016 Results: Angel Broking
Views on Hero Motocorp 1QFY2016 Results: Angel Broking
Views on HCL Technologies 4QFY2015 Results: Angel Broking
Views on Glaxo Pharmaceuticals 1QFY2016 Results: Angel Broking
Views on Alembic 1QFY2016 Results: Angel Broking
Views on ICICI Bank 1QFY2016 Results: Angel Broking
Views on Exide Industries Ltd 1QFY2016 Results: Angel Broking
BUY NRB Bearings: Anand Rathi Research
Views on Dr Reddys Lab 1QFY2016 Results: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2014